Next Article in Journal
All-Trans Retinoic Acid Increases DRP1 Levels and Promotes Mitochondrial Fission
Next Article in Special Issue
Never Change a Flowing System? The Effects of Retrograde Flow on Isolated Perfused Lungs and Vessels
Previous Article in Journal
Fibroblast Growth Factor Receptors (FGFRs) and Noncanonical Partners in Cancer Signaling
Previous Article in Special Issue
Sphingosine 1 Phosphate (S1P) Receptor 1 Is Decreased in Human Lung Microvascular Endothelial Cells of Smokers and Mediates S1P Effect on Autophagy
Perspective

Mesenchymal Stromal Cell Secretome for Post-COVID-19 Pulmonary Fibrosis: A New Therapy to Treat the Long-Term Lung Sequelae?

1
Department of Drug Sciences, University of Pavia, Viale Taramelli 12, 27100 Pavia, Italy
2
Center for Diagnosis of Inherited Alpha1-Antitrypsin Deficiency, Department of Internal Medicine and Therapeutics, Pneumology Unit IRCCS San Matteo Hospital Foundation, University of Pavia, 27100 Pavia, Italy
3
Pneumology Unit IRCCS San Matteo Hospital Foundation, 27100 Pavia, Italy
4
PharmaExceed S.r.l., 27100 Pavia, Italy
5
Complex Operative Unit of Pneumology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Catholic University of the Sacred Heart, 00168 Rome, Italy
*
Author to whom correspondence should be addressed.
Academic Editor: Stijn De Langhe
Cells 2021, 10(5), 1203; https://doi.org/10.3390/cells10051203
Received: 24 March 2021 / Revised: 23 April 2021 / Accepted: 13 May 2021 / Published: 14 May 2021
(This article belongs to the Special Issue The Endothelial Cell in Lung Inflammation)
To date, more than 100 million people worldwide have recovered from COVID-19. Unfortunately, although the virus is eradicated in such patients, fibrotic irreversible interstitial lung disease (pulmonary fibrosis, PF) is clinically evident. Given the vast numbers of individuals affected, it is urgent to design a strategy to prevent a second wave of late mortality associated with COVID-19 PF as a long-term consequence of such a devastating pandemic. Available antifibrotic therapies, namely nintedanib and pirfenidone, might have a role in attenuating profibrotic pathways in SARS-CoV-2 infection but are not economically sustainable by national health systems and have critical adverse effects. It is our opinion that the mesenchymal stem cell secretome could offer a new therapeutic approach in treating COVID-19 fibrotic lungs through its anti-inflammatory and antifibrotic factors. View Full-Text
Keywords: SARS-CoV-2; COVID-19; pulmonary fibrosis; mesenchymal stem cells; extracellular vesicles; microvesicles; exosomes; secretome SARS-CoV-2; COVID-19; pulmonary fibrosis; mesenchymal stem cells; extracellular vesicles; microvesicles; exosomes; secretome
MDPI and ACS Style

Bari, E.; Ferrarotti, I.; Saracino, L.; Perteghella, S.; Torre, M.L.; Richeldi, L.; Corsico, A.G. Mesenchymal Stromal Cell Secretome for Post-COVID-19 Pulmonary Fibrosis: A New Therapy to Treat the Long-Term Lung Sequelae? Cells 2021, 10, 1203. https://doi.org/10.3390/cells10051203

AMA Style

Bari E, Ferrarotti I, Saracino L, Perteghella S, Torre ML, Richeldi L, Corsico AG. Mesenchymal Stromal Cell Secretome for Post-COVID-19 Pulmonary Fibrosis: A New Therapy to Treat the Long-Term Lung Sequelae? Cells. 2021; 10(5):1203. https://doi.org/10.3390/cells10051203

Chicago/Turabian Style

Bari, Elia, Ilaria Ferrarotti, Laura Saracino, Sara Perteghella, Maria L. Torre, Luca Richeldi, and Angelo G. Corsico 2021. "Mesenchymal Stromal Cell Secretome for Post-COVID-19 Pulmonary Fibrosis: A New Therapy to Treat the Long-Term Lung Sequelae?" Cells 10, no. 5: 1203. https://doi.org/10.3390/cells10051203

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop